Contents

Non Melanoma Skin CancerEdit

Non-melanoma skin cancer refers to a group of skin cancers that arise from the epidermis and its appendages, most commonly basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Together, these cancers account for the vast majority of skin cancer diagnoses. When detected early, many lesions are highly curable with minimal morbidity; however, untreated tumors can invade locally and cause substantial tissue damage, especially on sun-exposed areas such as the face, ears, and neck. For context, these cancers are distinct from melanoma and other less common skin malignancies.

The incidence of non-melanoma skin cancer has risen in many populations, reflecting aging demographics and cumulative ultraviolet exposure. Risk is higher in people with light skin who burn easily, older individuals, men, people with chronic sun exposure, and those with immunosuppression or certain genetic conditions. Preventive measures, early detection, and access to effective treatment have substantial impacts on outcomes and quality of life. ultraviolet radiation exposure is a central factor, and public health efforts emphasize sun protection and avoidance of harmful UV sources, such as tanning beds. tanning bed and sun protection play important roles in prevention.

Overview

Non-melanoma skin cancer encompasses several entities, with BCC and SCC the most common. BCCs are typically slow-growing and less likely to metastasize, but they can cause significant local destruction if untreated. SCCs carry a higher risk of regional spread and, in rare cases, distant metastasis, particularly in lesions on the lip, ears, or other high-risk sites. The distinctions between these cancers are important for prognosis and management, and biopsies are used to confirm diagnoses and guide therapy. For diagnostic confirmation, clinicians rely on histopathology following a biopsy. See basal cell carcinoma and squamous cell carcinoma for deeper discussion of each tumor type.

Epidemiology

Non-melanoma skin cancers are among the most commonly diagnosed cancers worldwide. Incidence varies by geographic region, climate, skin type, and access to care. The diseases disproportionately affect individuals with light skin phenotypes and those with extensive sun exposure over a lifetime. Age is a major factor; the likelihood of developing NMSC increases with advancing years, reflecting cumulative UV damage. While the majority of NMSCs remain localized at diagnosis, a minority can recur after treatment or, in some cases, metastasize.

Pathophysiology and Classification

UV radiation from sun exposure causes DNA damage in skin cells, contributing to the development of BCC and SCC. The molecular pathways differ between subtypes but share common themes of mutations in tumor suppressor genes and altered cell-cycle control. For BCC, disruptions in hedgehog signaling are frequently involved, and targeted therapies have emerged for advanced disease. For SCC, mutations in processes governing DNA repair and cell proliferation contribute to tumor formation; immunotherapy has expanded treatment options for unresectable or metastatic cases. See basal cell carcinoma and squamous cell carcinoma for detailed mechanistic discussions.

Risk factors

  • Ultraviolet radiation exposure from sunlight and tanning devices. See ultraviolet radiation and tanning bed.
  • Light skin phototypes and fair complexion, which burn easily and have less protective melanin.
  • Age and male sex, associated with cumulative UV damage and differences in exposure patterns.
  • Immunosuppression, including drug-induced immune suppression after transplantation or in certain medical conditions. See immunosuppression.
  • Prior skin cancers and a history of significant sun exposure or sunburns.
  • Chronic ulcers or wounds and exposure to certain toxins, such as arsenic. See arsenic.
  • Genetic syndromes that predispose to skin cancer, such as certain connective tissue disorders or inherited cancer syndromes.

Diagnosis and staging

Initial assessment is clinical, followed by biopsy to confirm the diagnosis and establish histologic subtype. Dermoscopy can aid evaluation of suspicious lesions prior to biopsy. Once diagnosed, staging for non-melanoma skin cancers focuses on size, depth of invasion, location, and nodal involvement, guiding treatment decisions. See biopsy and dermoscopy for related topics.

Treatment

Treatment choices depend on tumor type, size, location, patient preference, and comorbidity. Common approaches include:

  • Surgical excision to remove the lesion with a margin of healthy tissue. See surgical excision.
  • Mohs micrographic surgery (for high-risk or cosmetically sensitive sites), which offers maximal tissue conservation with complete margin assessment. See Mohs surgery.
  • Curettage and electrodessication or electrodesiccation for small, superficial lesions.
  • Cryotherapy (freezing) for certain small, low-risk lesions.
  • Radiation therapy for patients who are not surgical candidates or for lesions in complex locations.
  • Topical therapies (e.g., imiquimod, 5-fluorouracil) for superficial or non-surgical lesions, particularly BCC subtypes.
  • For advanced or metastatic disease, systemic therapies including immune checkpoint inhibitors (e.g., cemiplimab) and, in some cases, hedgehog pathway inhibitors (e.g., vismodegib) for BCC. See cemiplimab and vismodegib.

Early-stage NMSCs are often curable with straightforward treatment and yield excellent long-term outcomes, while more advanced or high-risk lesions require multidisciplinary management.

Prevention

Prevention emphasizes reducing UV exposure, using protective clothing and broad-spectrum sunscreen, avoiding tanning beds, and performing regular skin checks, especially for high-risk individuals. Public health messaging and patient education aim to lower incidence and encourage timely evaluation of suspicious lesions. See sun protection and prevention discussions in related literature.

Controversies and debates

Within the field, there is ongoing discussion about screening and early detection strategies. Some health systems do not endorse broad population-wide skin cancer screening due to questions about cost-effectiveness and potential overdiagnosis, while others advocate targeted screening for high-risk groups. The balance between early intervention and overtreatment remains a topic of clinical and policy debate. In treatment, optimal sequencing of therapies for advanced disease and access to emerging treatments—such as immunotherapies and targeted agents—continue to evolve as evidence accumulates. See discussions around screening and immunotherapy in related sections of the literature.

See also